160145-83-5

Basic information

• Product Name: Telithromycin intermediate (7A)
• Synonyms: 2'-OBEZOYL-3-O-DE[(2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-ALPHA-L-RIBOHEXOPYRANOSYL)OXY]-11-DEOXY-10,11-DIDEHYDRO-12-O-[(1H-IMIDAZOL-1-YL)CARBONYL]-6-O-METHYL-3-OXO-ERYTHROMYCIN;2'-OBEZOYL-3-O-DE[(2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-Α-L-RIBOHEXOPYRANOSYL)OXY]-11-DEOXY-10,11-DIDEHYDRO-12-O-[(1H-IMIDAZOL-1-YL)CARBONYL]-6-O-METHYL-3-OXOERYTHROMYCIN (7A);Telithromycin intermediate (7A);2 ∧ -OBEZOYL -3-O-DE [(2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-α-L-RIBOHEXOPYRANOSYL) OXY]-11-DEOXY-10,11-DIDEHYDRO-12-O-[(1H-IMIDAZOL-1-YL) CARBONYL]-6-O-METHYL-3-OXO ERYTHROMYCIN;Imidazol-1-Yl)Carbonyl]-6-O-Methyl-3-Oxo-Erythromycin;Inter.OfTelithromycin;2 '' -OBEZOYL -3-O-DE [(2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-A-L-RIBOHEXOPYRANOSYL) OXY]-11-DEOXY-10,11-DIDEHYDRO-12-O-[(1H-IMIDAZOL-1-YL) CARBONYL]-6-O-METHYL-3-OXO ERYTHROMYCIN
• CAS NO: 160145-83-5
• Molecular Formula: C₃₆H₅₅N₃O₁₁
• Molecular Weight: 767.911
• Mol File: 160145-83-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 352.1 °C at 760 mmHg
• Flash Point: 166.7 °C
• Appearance: /
• Density: 1.15 g/cm³
• PKA: 10.72±0.70(Predicted)
• CAS DataBase Reference: Telithromycin intermediate (7A)(CAS DataBase Reference)
• NIST Chemistry Reference: Telithromycin intermediate (7A)(160145-83-5)
• EPA Substance Registry System: Telithromycin intermediate (7A)(160145-83-5)

Safety Data

• Hazardous Substances Data: 160145-83-5(Hazardous Substances Data)

Usage

General Description

Telithromycin intermediate (7A) is a chemical compound used in the synthesis of the antibiotic telithromycin. It is an important precursor in the manufacturing process of this antibiotic, which is used to treat respiratory tract infections. Telithromycin intermediate (7A) undergoes various chemical reactions and modifications to ultimately form telithromycin. This intermediate plays a crucial role in the production of telithromycin and is essential for the final formulation of the antibiotic.

Upstream product

• 198782-60-4 (2S,3R,4S,6R)-4-(dimethylamino)-2-(((3R,4S,5S,6R,7R,9R,13S,14R,E)-14-ethyl-4,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradec-11-en-6-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl acetate 
• 198782-59-1 10,11-anhydro-6-O-methyldescladinosylerythromycin A 
• 144604-03-5 (10E)-10,11-didehydro-11-deoxy-6-O-methylerythromycin 
• 160145-81-3 Acetic acid (2S,3R,4S,6R)-4-dimethylamino-2-((3R,5R,6R,7R,9R,11R,12R,13R,14R)-14-ethyl-13-hydroxy-12-methanesulfonyloxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,4,10-trioxo-oxacyclotetradec-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 143353-82-6 Acetic acid (2S,3R,4S,6R)-4-dimethylamino-2-((3R,5R,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyl-2,4,10-trioxo-oxacyclotetradec-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 143353-81-5 3-Ode-[(2,6-dideoxy-3-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methylerythromycin 2￠-acetate 
• 118058-74-5 3-O-descladinosylclarithromycin 
• 81103-11-9 clarithromycin 
• 530-62-1 1,1'-carbonyldiimidazole 
• 214694-76-5 2'-O-acetyl-10,11-didehydro-11-deoxy-3-O-descladinosyl-3-oxo-6-O-methyl-erythromycin A 

Downstream Products

• 191114-48-4 telithromycin 
• 143353-30-4 (3aS,4R,7R,9R,10R,11R,13R,15aR)-10-((2S,3R,4S,6R)-4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-(4-phenyl-butyl)-octahydro-3,5-dioxa-1-aza-cyclopentacyclotetradecene-2,6,8,14-tetraone 

Relevant articles and documents

An Approach to Modify 14-Membered Lactone Macrolide Antibiotic Scaffolds

A ketolide derivative with (12R)-configuration was obtained via a novel ketene acetal in acidic conditions. The structure of this atypical β-keto ketene acetal intermediate within the macrocyclic system has been determined by NMR and X-ray methods. The use of basic conditions at an elevated temperature yielded new, doubly α,β-unsaturated ketone macrolide derivatives with (4E)-configuration as two conformational isomers of folded-in or folded-out conformations.

PROCESS FOR THE PRODUCTION OF TELITHROMYCIN

The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of superior stability and purity.